Lombard holds on to Q4 US approval for Aorfix despite FDA questions
This article was originally published in Clinica
Executive Summary
The US FDA has requested from Lombard Medical Technologies responses to some questions raised during the review of the latter's premarket approval application for Aorfix, the UK company's stent graft for the endovascular repair of abdominal aortic aneurysms. London-based Lombard said that the "short list" of questions were "relatively straightforward" and intends to submit its answers to the FDA before the end of the month. The company said it still expects Aorfix to clear the US regulatory hurdle within the fourth quarter, although the approval process may be subject to delays beyond its control and there is "a risk" approval for Aorfix "may slip into the first quarter of 2013".
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.